<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054442</url>
  </required_header>
  <id_info>
    <org_study_id>MOHN01</org_study_id>
    <secondary_id>2013-002886-20</secondary_id>
    <secondary_id>DHNS 2013-01</secondary_id>
    <nct_id>NCT02054442</nct_id>
  </id_info>
  <brief_title>A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck</brief_title>
  <acronym>COMMENCE</acronym>
  <official_title>A Phase Ib-II Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. A Study of the Dutch Head and Neck Society</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Centre Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform a randomized phase II study to investigate if the addition of&#xD;
      cetuximab to MTX is beneficial for the patient. Because no data on this combination are&#xD;
      available the investigators will start with a phase Ib study to investigate the feasibility&#xD;
      of the schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The addition of cetuximab to cisplatin and 5-FU in recurrent or metastatic squamous cell&#xD;
      carcinoma of the head and neck (SCCHN) showed an improvement of overall survival (OS),&#xD;
      progression free survival (PFS) and response rate (RR). However, cisplatin and 5-FU are toxic&#xD;
      cytostatics for the vulnerable recurrent or metastatic SCCHN patient. As one of the primary&#xD;
      goals in these patients is palliation, in some patients treatment with cisplatin, 5-FU and&#xD;
      cetuximab is not feasible owing to a low performance score (PS of 2) or the patient refusal&#xD;
      to receive chemotherapy, i.e. cisplatin and 5-FU, possibly influencing quality of life&#xD;
      negatively.&#xD;
&#xD;
      Methotrexate is a cytostatic which has shown to have modest activity in recurrent or&#xD;
      metastatic SCCHN. The RR is between 14 and 20%, the median PFS is 3 months, and there is no&#xD;
      improvement in OS, which is only 6 months. Toxicity of MTX is very low. Patients with a PS of&#xD;
      2 can be treated with MTX. Patients refusing treatment with cisplatin, 5-FU and cetuximab,&#xD;
      frequently choose MTX as palliative treatment.&#xD;
&#xD;
      No data are available on the combination of cetuximab and MTX. The investigators will perform&#xD;
      a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial,&#xD;
      i.e. an improvement in the PFS, for the patient. Because no data on this combination are&#xD;
      available the investigators will start with a phase Ib study to investigate the feasibility&#xD;
      of the schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>During the first 4 weeks after start of the combination MTX and cetuximab</time_frame>
    <description>In the phase Ib study: toxicity scored with CTC v 4.0*; incidence of dose limiting toxicity (DLT) during the first 4 weeks after start of the combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>In the phase II study: progression free survival (PFS). The analysis of PFS can be performed as soon as the target event (progression or death) has been observed in 98 of the 114 subjects randomized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Followed up to 12 months after randomization</time_frame>
    <description>Overall survival (OS) The analysis of OS can be performed as soon as the target event has been observed in 98 of the 114 subjects randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>Till end of treatment</time_frame>
    <description>The difference in RR rates between both treatment arms will be analyzed using a stratified Cochran Mantel Haenszel test at a one-sided alpha-level of 0.05. In addition to the response rates in both arms, the odds ratio will be reported together with 90% confidence intervals. The impact of various demographic and disease characteristics (e.g. HPV positivity), on RR will be investigated using an exploratory logistic regression model.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm A: MTX in combination with cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.&#xD;
Premedication: H1-receptor antagonist and dexamethasone.&#xD;
The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.&#xD;
Premedication: ondansetron 8 mg.&#xD;
Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.&#xD;
Premedication: ondansetron 8 mg.&#xD;
Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.</description>
    <arm_group_label>Arm A: MTX in combination with cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
    <other_name>L01XC06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Arm A: MTX in combination with cetuximab</arm_group_label>
    <arm_group_label>Arm B: MTX</arm_group_label>
    <other_name>EMTHEXATE</other_name>
    <other_name>L01BA01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologically/histologically-proven SCCHN&#xD;
&#xD;
          -  Recurrent or metastatic SCCHN&#xD;
&#xD;
          -  At least one measurable lesion as determined by RECIST v1.1 is required. Lesions in&#xD;
             previously irradiated areas should not be considered measurable unless there is clear&#xD;
             evidence of progression in such lesions since the radiotherapy.&#xD;
&#xD;
          -  No prior systemic treatment for recurrent or metastatic disease&#xD;
&#xD;
          -  Primary site: (1) oral cavity, (2) oropharynx, (3) hypopharynx, (4) larynx, or (5)&#xD;
             unknown primary squamous cell carcinoma in the head and neck region presenting&#xD;
             originally with lymph node metastases (N1-N3).&#xD;
&#xD;
          -  Time between prior treatment and inclusion in the study (&gt; 3 months). Palliative RT in&#xD;
             case of painful bone metastases is allowed in phase II and after 4 weeks in phase Ib&#xD;
&#xD;
          -  Ineligible (due to medical co-morbidities) or intolerant to platinum-based therapy per&#xD;
             medical history or refusing cisplatin-based chemotherapy by the patient&#xD;
&#xD;
          -  WHO performance status 0-2.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Adequate organ function and laboratory parameters as defined by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L&#xD;
&#xD;
               -  Hemoglobin (Hb) ≥ 9 g/dl 5.6 mmol/l (which may be achieved by transfusion)&#xD;
&#xD;
               -  Platelets (PLT) ≥ 100 x 109/L&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN (upper limit of normal)&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Calculated creatinine clearance or MDRD &gt; 60ml/min&#xD;
&#xD;
          -  Recovered from all adverse events (AEs) of previous anti-cancer therapies. AEs related&#xD;
             to prior radiotherapy are allowed.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious active infections&#xD;
&#xD;
          -  Patients (M/F) with reproductive potential not implementing adequate contraceptives&#xD;
             measures&#xD;
&#xD;
          -  Prior treatment with EGFR inhibitors or MTX&#xD;
&#xD;
          -  Concomitant (or within 4 weeks before randomization) administration of any other&#xD;
             experimental drug under investigation&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy.&#xD;
&#xD;
          -  Central nervous system involvement&#xD;
&#xD;
          -  Lung fibrosis&#xD;
&#xD;
          -  Pleural effusion or ascites or other third space effusions&#xD;
&#xD;
          -  History of another malignancy within 2 years prior to starting study treatment, except&#xD;
             cured basal cell carcinoma of the skin, excised carcinoma in situ of the cervix, or&#xD;
             other head and neck cancer.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any other condition that would, in the Investigator's judgment, preclude patient's&#xD;
             participation in the clinical study due to safety concerns or compliance with clinical&#xD;
             study procedures, e.g. infection/inflammation, intestinal obstruction,&#xD;
             social/psychological complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla M van Herpen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Centre Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>methotrexate</keyword>
  <keyword>squamous cell carcinoma head neck</keyword>
  <keyword>palliative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

